Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study

Basit Öğe Kaydı
dc.authorid0000-0002-2049-1316
dc.contributor.authorTopaloğlu Demir, Filiz
dc.contributor.authorÖzkök Akbulut, Tuğba
dc.contributor.authorKıvanç Altunay, İlknur
dc.contributor.authorAytekin, Sema
dc.contributor.authorTopal, İlteriş Oğuz
dc.contributor.authorKara Polat, Asude
dc.contributor.authorÖzkur, Ezgi
dc.contributor.authorKaradağ, Ayşe Serap
dc.date.accessioned2021-01-27T08:14:57Z
dc.date.available2021-01-27T08:14:57Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalı
dc.description.abstractThe objective was to reveal and compare the adverse effects of infliximab, etanercept, adalimumab, ustekinumab and secukinumab, and determine possible risk factors. The follow-up files and computer-based records of patients with psoriasis were retrospectively screened between January 2007 and September 2019. The five biological agents were compared in terms of their adverse effects, and factors that might be related to these effects were explored. While there was no statistically significant difference between the agents in terms of the rate of serious adverse effects, when all the adverse effects were evaluated together, the highest rate was seen in the use of infliximab and the lowest in secukinumab (P= .001). The rates of adverse effects and related drug discontinuation were higher in the use of anti-TNF agents compared to interleukin inhibitors (P= .004 andP= .012, respectively). The agent with the highest drug discontinuation rate due to adverse effects was infliximab while the least discontinued agent was ustekinumab (P= .036). There were more side effects with anti-TNF than interleukin inhibitors, but the serious adverse effect rate was similar in both groups. The incidence of certain adverse effects increases depending on age, number of comorbidities, biological agent and its group, concomitant systemic therapy, and use of multiple agents.
dc.identifier.citationTopaloğlu Demir, F., Özkök Akbulut, T., Kıvanç Altunay, İ., Aytekin, S., Topal, İ. O., Kara Polat, A. ... Karadağ, A. S. (2020). Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study. Dermatologic Therapy, 33(6). https://dx.doi.org/10.1111/dth.14216
dc.identifier.doi10.1111/dth.14216
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.issue6
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.1111/dth.14216
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6410
dc.identifier.volume33
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofDermatologic Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAdverse Effects
dc.subjectBiological Agents
dc.subjectPsoriasis
dc.subjectSafety
dc.titleEvaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Topaloglu-Filiz-2020.pdf
Boyut:
1.41 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu